
Posts Tagged ‘small cap’
VIDEO – @goplantx $VEGA $PLTXF is the One-Stop-Shop for Everything Plant-Based $VERY.ca $MEAT.ca $EATS.ca $VEGN.ca

Limitless Integrations to Utilize Draganfly $DFLY.ca $DFLYF Drones and AI Technology to Integrate Into its Mobile Onsite Detection Platform $FLT.ca $UAVS $ALPP

- Announced that it will provide drones and the Vital Intelligence detection AI technology for integration with the patent pending iDENT Mobile Onsight Detection Systems (“MODS”) offered by Limitless Integrations LLC
- iDENT MODS platform is a self-contained turn-key entrance gateway designed to be rapidly deployed to locations requiring secure high throughput flow with instant secure access into any venue
Los Angeles, CA, Feb. 17, 2021 — Draganfly Inc. (OTCQB: DFLYF) (CSE: DFLY) (FSE: 3U8) (“Draganfly” or the “Company”), award-winning, industry-leading drone solutions, and systems developer, today announced that it will provide drones and the Vital Intelligence detection AI technology for integration with the patent pending iDENT Mobile Onsight Detection Systems (“MODS”) offered by Limitless Integrations LLC (“Limitless Integrations”).
The iDENT MODS platform is a self-contained turn-key entrance gateway designed to be rapidly deployed to locations requiring secure high throughput flow with instant secure access into any venue. The iDENT MODS can be utilized at festivals, worksites, military security perimeters, emergency response locations, and any scenario with high traffic volumes that require instant security.
With over 25 years of experience, Limitless Integrations offers its clients high-quality, reliable commercial and industrial physical security and health safety solutions. These solutions are specifically designed to meet the unique demands of venues and facilities of any size.
Draganfly will provide drones, tethered or otherwise for observation and threat detection for the perimeters where the Limitless iDENT MODS platforms are being utilized. The software on the drones can be used for general observation and security including possible weapons detection.
“Draganfly will provide the perfect partnership in enabling our MODS units to have a thorough screening process by way of their Vita Intelligence Technology delivered by drones,” said TJ Dooley CEO and co-founder of Limitless Integrations. “The technology solution that Draganfly offers will enhance the ability for our clients across a multitude of industries to provide a safe experience.”
“Draganfly is honored to have its technology and drones integrated into the incredible Limitless iDENT MODS platform. Helping provide the ability to securely and safely open venues or critical locations such as emergency response scenarios.”
Read More: https://agoracom.com/ir/Draganfly/forums/discussion/topics/755500-limitless-integrations-to-utilize-draganfly-drones-and-ai-technology-to-integrate-into-its-mobile-onsite-detection-platform/messages/2304012#message
@goplantx $VEGA $PLTXF Prices Offering and Files Amended and Restated Preliminary Short Form Prospectus $VERY.ca $MEAT.ca $EATS.ca $VEGN.ca

- Filed an amended and restated short form preliminary short form prospectus in connection with the Offering.
- The Offering will be at a price of $1.25 per unit of the Company for the issuance of a minimum of 8,000,000 Units to raise minimum total gross proceeds of $10,000,000 .
- The Offering, which will be conducted on a “best efforts” agency basis, is being led by Mackie Research Capital Corporation as lead agent and sole bookrunner.
VANCOUVER, BC , Feb. 17, 2021 – PlantX Life Inc. (the ” Company ” or ” PlantX “) (CSE: VEGA ) (Frankfurt: WNT1) (OTCQB: PLTXF) is pleased to announce that it has priced its previously announced offering (the ” Offering “) in its February 16, 2021 news release and has today filed an amended and restated short form preliminary short form prospectus in connection with the Offering. The Offering will be at a price of $1.25 per unit of the Company (a ” Unit “) for the issuance of a minimum of 8,000,000 Units to raise minimum total gross proceeds of $10,000,000 . The Offering, which will be conducted on a “best efforts” agency basis, is being led by Mackie Research Capital Corporation (the ” Agent “) as lead agent and sole bookrunner.

Each Unit will consist of one (1) common share of the Company (an ” Unit Share “, each such common share in the authorized capital structure of the Company, a ” Common Share “) and one (1) Common Share purchase warrant (a ” Warrant “). Each Warrant will be exercisable at a price of $1.45 and will entitle the holder to purchase one additional Common Share (a ” Warrant Share “) for a period of two (2) years from the closing of the Offering (the ” Closing “), provided that , if, at any time, the daily volume weighted average trading price (or closing price on trading days when there are no trades) of the Common Shares on the Canadian Securities Exchange (the ” CSE “) or, if the Common Shares are not listed on the CSE, then on such other recognized Canadian stock exchange on which the Common Shares are then listed, equals or exceeds $2.50 per Common Share over any ten (10) consecutive trading days, the Company shall be entitled, at its option, within ten (10) business days following such ten-day period, to accelerate the exercise period of the Warrants through the issuance of a press release (the ” Acceleration Notice “) specifying the new expiry date and, in such case, the Warrants will expire on the 30th day following the issuance of the Acceleration Notice. From and after the new expiry date specified in such Acceleration Notice, no Warrants may be issued or exercised, and all unexercised Warrants shall be void and of no effect following the new expiry date.
The net proceeds raised under the Offering will be used to fund expansion, to continue to develop a user app, to evaluate and pursue potential strategic acquisitions, and for working capital and general corporate purposes.
The closing of the Offering is currently expected to be on or about March 11, 2021 or such other date as agreed upon between the Company and the Agent, and is subject to certain conditions including, but not limited to, the execution of an agency agreement and the receipt of all necessary regulatory approvals including the approval of the CSE.
The Units are to be sold on a “best efforts” basis through the Agent in the provinces of British Columbia , Alberta and Ontario , and such other jurisdictions as the Agent and the Company may agree other than Quebec , and in the United States pursuant to available exemptions from the registration requirements of the United States Securities Act of 1933, as amended (the ” U.S. Securities Act “) and all applicable U.S. state securities laws.
This press release does not constitute an offer to sell or a solicitation of an offer to buy any of these securities in the United States or to, or for the account or benefit of, U.S. persons. The securities described herein have not been and will not be registered under the U.S. Securities Act or any state securities laws and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. “United States” and “U.S. person” are as defined in Regulation S under the U.S. Securities Act.
Read More: https://agoracom.com/ir/PlantX/forums/discussion/topics/755495-plantx-prices-offering-and-files-amended-and-restated-preliminary-short-form-prospectus/messages/2304002#message
Valeo Pharma’s $VPH $VPHIF Hesperco Capsules at the Core of Montreal Heart Institute’s Hesperidin Coronavirus Clinical Trial $HLS.ca $MDP.ca $GUD.ca $RX.ca

- Montreal Heart Institute study to evaluate the ability of hesperidin, the medicinal ingredient in Hesperco™ capsules, to reduce the severity of symptoms and the need for hospitalization in COVID-19 patients
- Hesperidin interferes / inhibits 2 key proteins of SARS-CoV-2 necessary for entry and infection of cells, suggesting that hesperidin may disrupt the replication rate of the virus and enable infected patients to build natural immunity
- Hesperidin’s safety profile and immune-modulatory activity make it a highly promising molecule to intervene at various stages of the COVID-19 infection process
- Hesperco TM capsules contain 500mg of high purity concentrated hesperidin
MONTREAL , Feb. 17, 2021 – Valeo Pharma Inc . ( CSE:VPH) (OTCQB:VPHIF) (FSE:VP2 ) (” Valeo ” or the ” Company “), a Canadian pharmaceutical company and its Hesperco™ development partner, Ingenew Pharma Inc. (“Ingenew”), are pleased to announce that Hesperco TM capsules, approved by Health Canada for immune support, will be at the core of the Montreal Heart Institute’s (“MHI”) clinical trial, “The Hesperidin Coronavirus Study”.
The MHI’s study will evaluate the effect of hesperidin on COVID-19 symptoms and its ability to reduce disease severity and the need for hospitalization in patients with COVID-19. The randomized, double-blind, placebo controlled study will enroll 216 confirmed COVID-19 symptomatic patients.
“The immune support properties of hesperidin, the medicinal ingredient contained in HESPERCO™ capsules, and its efficacy against other coronavirus strains are well documented in scientific literature. We are extremely proud to contribute in the fight against the COVID-19 virus with the prestigious MHI and our development partner Ingenew”, said Steve Saviuk , Valeo’s CEO. “Our involvement in this study aligns well with our vision to build a Canadian anchor pharmaceutical company and continued commitment to provide Canadian healthcare professionals and patients with innovative solutions to improve quality of life”.
Commenting on the Montreal Heart Institute’s Hesperidin Coronovirus Study, Pierre Laurin , President and CEO of Ingenew, said: “We are pleased that MHI’s scientists concur with our scientific findings.”
Read More: https://agoracom.com/ir/ValeoPharma/forums/discussion/topics/755488-valeo-pharma-s-hesperco-capsules-at-the-core-of-montreal-heart-institute-s-hesperidin-coronavirus-clinical-trial/messages/2303992#message
VIDEO – DraganFly $DFLY.ca $DFLYF and Windfall Geotek Landmines Solution Is a $700M Annual Market Whose Biggest Payoff Is Lives Saved $FLT.ca $UAVS $ALPP

DraganFly ($DFLY) and Windfall Geotek ($WIN) have combined world-class drone technology with artificial intelligence to create an “incomparable solution” solving the global landmine epidemic.
With 60 – 110 million landmines needed to be found, the market is estimated to be worth $700M per year … But that pales in comparison to the value of lives that will be saved and economic prosperity created from ridding regions plagued by landmines.
VIDEO – Predictiv AI $PAI.ca $INOTF Is Already Commercializing Artificial Intelligence Driven Thermal Scanners With 62 Orders and 6 Channel Partners

Our thesis at AGORACOM is that small cap disruptive technology companies are going to create 3X more wealth this decade than the last 3 decades combined, thanks to the convergence of powerful tech such as Artificial Intelligence, IoT sensors and so on.
Why? The costs to develop, deploy and scale new applications powered by these new technologies have come down to a point where small cap companies can compete head to head with just about anybody. In fact, their size makes them more nimble and able to pivot into emerging trends much quicker than most tech giants.
Which companies will actually succeed in delivering is a determination you have to make. But one company to consider is Predictiv AI (PAI:TSXV / INOTF:OTCQB), whose proprietary artificial intelligence and machine learning platform provides predictive and prescriptive solutions in the public safety sector.
In layman’s terms, PAI uses AI and Machine learning to create solutions that can predict danger.
For example, the Company’s Thermal Pass Fever Detection System was recently used at a Carolina Panthers NFL game. Watch this short video to see it in action. Highlights of the system include:
- 24 medical grade sensors
- 1,200 readings per second
- 1 person / second
As you can imagine, Thermal Pass can be used for almost any high-traffic location you can think of. But the big question is …. will anybody actually use it? Because truth be told 99% of us are not in a position to be able to assess how any AI solutions of any company stack up against the competition. The only thing we can rely on is AGORACOM’s favourite metric – 3rd party acceptance. In short, if your product is good, people will want it.
By that measure, PAI is off to a great start with:
- Orders for 62 units of ThermalPass since commercial launch in October. Impressive.
- Orders include hospitals, long-term care facilities, prisons and public schools. More impressive
- 6 channel partners. This is really impressive because channel partners don’t waste their valuable time and resources with products they don’t think they can sell
3rd party acceptance at this early stage – CHECK
Watch our interview with Michael Lende in which we do a deep dive into PAI tech, products and future plans.
VIDEO – AGORACOM Beyond The Expert Welcomes Venture Capitalist Leigh Hughes To Discuss Mountain Valley MD $MVMD, Valeo Pharma $VPH $VPHIF and Xphyto Therapeutics $XPHY $XPHYF

AGORACOM followers have given us great feedback on our hit series “Beyond The Press Release” (BTPR) in which we speak with small cap CEO’s about important press releases in greater depth and, quite frankly, in layman’s terms for investors to truly understand their significance.
Nowhere is this more important than in the world of disruptive technologies, biotech and pharma. Each of these industries share two distinct traits:
- The possibility for explosive growth with disruptive new products
- Difficulty in conveying disruptive new products that, by their nature, have never been seen before by investors.
Whereas BTPR tells these stories from the side of small cap public companies, Beyond The Expert (BTE) tells these stories from the perspective of experts on these topics – and we couldn’t think of anyone better to start off this series than Leigh Hughes.
Leigh is a Venture Capitalist who I’ve personally watched conduct incredible due diligence and invest into many small cap companies that have generated incredible returns over 12-18 month periods.
Leigh is so good at what he does that many global private equity funds and institutions take his call and often follow him into investments he chooses to make. Moreover, he serves as an advisor to several small cap companies.
If you ever wanted to truly learn how to become a great small cap investor, it doesn’t get much better than this.
Without further adieu, watch this great interview with Leigh Hughes and make sure to provide us with your feedback via comments on Twitter, YouTube or wherever you may be watching or listening.
Draganfly $DFLY.ca $DFLYF and Windfall Geotek Advance Testing of Drone-Based #AI Solution for Landmine Detection $FLT.ca $UAVS $ALPP

- Announced that it has advanced field testing of the EagleEye™ land mine detection solution with Windfall Geotek (TSX-V: WIN) (OTCQB: WINKF).
- Windfall Geotek is a mining services company and a leader in the use of Artificial Intelligence (AI) and advanced knowledge-extraction techniques since 2005 in the mining sector.
- This test included joint research, AI development, and engineering support for the development of drones and sensor equipment.
Los Angeles, CA., Feb. 11, 2021 — Draganfly Inc. (OTCQB: DFLYF) (CSE: DFLY) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems developer, today announced that it has advanced field testing of the EagleEye™ land mine detection solution with Windfall Geotek (TSX-V: WIN) (OTCQB: WINKF).
Windfall Geotek is a mining services company and a leader in the use of Artificial Intelligence (AI) and advanced knowledge-extraction techniques since 2005 in the mining sector. This test included joint research, AI development, and engineering support for the development of drones and sensor equipment.
Every day approximately 10 people around the world lose their lives or are maimed due to an anti-personnel mine (” APM “). This means that about 4,200 people are hurt or killed worldwide every year of which 35-42% are estimated to be children. It is estimated that there are between 60-110 million landmines in the ground right now and an equal amount is in stockpiles waiting to be planted or destroyed. Approximately 82 countries around the world are contaminated by APMs. Source: United Nations, Office for Disarmament Affairs .
An estimated US$540,000,000 was spent by industry and government in 2018 to deal with this problem of Landmines and Explosive Remnants of war (identify multiple APM and improvised explosive devices (IEDs) in a variety of terrain and contexts). Source: Landmine Monitor Report 2019 .
“Since 2020, Draganfly has invested in new capabilities in drone-based magnetometer technology and other remote sensing equipment,” commented Dinesh Kandanchatha, Chairman of Windfall Geotek. “The depth of the Draganfly engineering team, drone services group, and expert advisory in public safety was instrumental to get us to these first tests.”
“Windfall Geotek is the industry leader in AI-based digital exploration for mining. We now have the right mixture of equipment and data to move to the commercialization of an advanced AI-based platform to help solve the global problem of landmines,” said Cameron Chell, CEO of Draganfly. “The two companies share a mission of saving lives through technology. These tests are critical to helping create a new solution to this age-old problem. The new and expanded revenue streams for both companies in the Defense sector, Public Safety, and other markets are significant and represent an area where combined offering can excel.”
“For years our foundation has support organizations removing land mines, this type of technology and innovation by Draganfly and Windfall is exactly what is needed to solve this global challenge on a massive scale,” said Admiral Hayward, former head of the US Navy and member of the Joint Chiefs of Staff.
Watch the video to learn more.
